Immunotherapy vs Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer Blake Buzzard, PharmD; Hanna Zaghloul, PharmD; Monica Chintapenta, PharmD; Godsfavour Umoru, PharmD, Eric Bernicker, MD PURPOSE
RESULTS
The purpose of this study is to compare front-line treatment of advanced NSCLC utilizing immunotherapy alone versus chemoimmunotherapy, particularly according to PD-L1 expression.
A total of 164 patients were evaluated and 59 patients met inclusion criteria, 31 in the immunotherapy group and 28 in the chemoimmunotherapy group. The mean number of cycles completed were 11 vs 7 in the immunotherapy compared to chemoimmunotherapy groups respectively. For patients with PD-L1 expression at 1-49%, the mean cycles in the two groups were 7 vs 7. In patients with PD-L1 expression greater than or equal to 50%, the mean cycles completed were 12 vs 9. The number of patients discontinuing therapy due to progression was 18 (58%) vs 9 (32%) respectively. The number of patients discontinuing therapy due to adverse events was 7 (23%) vs 15 (54%).
METHODS
This is a retrospective cohort study of oncology patients newly diagnosed with advanced NSCLC and received treatment at Houston Methodist Hospital between November 2016 and December 2019. Patients received either pembrolizumab or atezolizumab monotherapy or pembrolizumab combined with platinum-based chemotherapy. The study is approved by the hospital’s institutional review board. The primary objective is to determine the number of completed treatment cycles of immunotherapy monotherapy compared to immunotherapy with platinum-based chemotherapy. Secondary endpoints will include PD-L1 expression, adverse effects, dose reduction and rationale, type of second-line therapy, and number of completed cycles of second-line therapy.
CONCLUSION
Immunotherapy provided a similar time-to-treatment discontinuation compared to immunochemotherapy, even within the patients with PD-L1 expression 1-49% and demonstrated less incidence of treatment discontinuation due to side effects.
PGY2 ONCOLOGY PHARMACY RESIDENCY
Blake A Buzard, PharmD Blake Buzard earned his BS in Pharmaceutical Sciences and PharmD from University of Kansas in 2019. He completed his PGY1 residency at Ascension Via Christi in Wichita, Kansas Following completion of his PGY2, Blake will move into an oncology clinical specialist role at St. Luke’s Hospital in Kansas City. Primary project preceptor: Hanna Zaghloul, PharmD, BCOP Presented at: 2020 Virtual Vizient Pharmacy Network, HOPA 2021, 2021 Virtual Midwest Pharmacy Residents Conference 2021.
26
|
